Phase Difference-Enhanced Magnetic Resonance (MR) Imaging (PADRE) Technique for the Detection of Age-Related

Yasuko Tatewaki1,2,3, Tatsushi Mutoh1, Benjamin Thyreau2

  • 1Department of Nuclear Medicine and Radiology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Miyagi, Japan.

Insights

Phase difference-enhanced imaging (PADRE) MRI shows optic radiation (OR) volume is preserved with age. PADRE detects age-related signal intensity changes in the OR, aiding future neurodegeneration studies.

Area of Science:

  • Neuroimaging
  • White Matter Tract Analysis
  • Radiology

Background:

  • The optic radiation (OR) is a critical white matter pathway connecting visual processing centers.
  • Phase difference-enhanced imaging (PADRE) offers precise OR delineation.
  • Understanding age-related changes in the OR is vital for neurodegenerative disease research.

Purpose of the Study:

  • To evaluate the effect of aging on optic radiation (OR) volume and signal intensity using PADRE MRI.
  • To establish a normative volumetric reference for the OR in a healthy population.
  • To compare PADRE findings with diffusion tensor imaging (DTI) for OR analysis.

Main Methods:

  • 39 healthy volunteers underwent 3.0-T MRI with PADRE and DTI sequences.
  • Manual tracing was used for PADRE-based OR volumetric analysis.
  • Automated thresholding was employed for DTI-based OR volumetric analysis.

Main Results:

  • Mean right and left OR volumes were 1469.0±242.4 mm³ and 1372.6±310.2 mm³ respectively.
  • OR volume did not significantly correlate with age.
  • Normalized OR signal intensity showed a significant linear correlation with increasing age (r²=0.50-0.53; P<0.01).
  • PADRE and DTI quantitative parameters for the OR showed significant correlations (r²=0.46-0.49; P<0.01).

Conclusions:

  • PADRE MRI demonstrates excellent preservation of optic radiation (OR) volume across age groups.
  • PADRE is sensitive to age-related alterations in OR signal intensity.
  • This technique holds promise for future investigations of neurodegenerative conditions like glaucoma and multiple sclerosis.